30.0 F
AOD-9604
Also known as: AOD9604, hGH Fragment 176-191
Emerging Research Category 2 Restricted
Research Evidence 10.0/100
Safety Profile 50.0/100
0 Clinical Trials
No clinical trials registered for this peptide.
17 Research Papers
- Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord unknown
- Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci unknown
- Human sports drug testing by mass spectrometry. Mass Spectrom Rev Review
- Detection and in vitro metabolism of AOD9604. Drug Test Anal unknown
- Identification and characterization of peptide drugs in unknown pharmaceutical preparations seized by the Belgian authorities: case report on AOD9604. Drug Test Anal unknown
Showing 5 of 17 papers by citation count.
FDA Data
Not FDA-Approved
AOD-9604 has not been evaluated by the FDA for safety or efficacy. It is not approved for human therapeutic use in the United States.
This peptide is classified as FDA Category 2 — it is prohibited from use in compounding pharmacies effective 2024. Obtaining it requires unregulated sources.
Frequently Asked Questions
Is AOD-9604 FDA approved?
No, AOD-9604 is not FDA approved. It is classified as FDA Category 2 and is banned from compounding pharmacies.
What is the trust score for AOD-9604?
AOD-9604 has a CheckPeptides trust score of 30.0/100 (grade: F). This score is based on clinical trial volume, research paper quality, FDA data, and evidence classification.
Last verified: April 7, 2026
Quick Facts
- Classification
- Growth hormone fragment
- Molecular Weight
- 1815.1 Da
- PubChem
- CID 71300630 ↗
- Regulatory Status
- N/A
Score Breakdown
Research Evidence 10.0/100
Safety Profile 50.0/100
Evidence Summary
- Clinical Trials
- 0
- Research Papers
- 17
- Trust Score
- 30.0/100
- Grade
- F